BAY 1135626
BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research[1].
Product Specifications
CAS Number
1404071-37-9
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bay-1135626.html
Purity
99.19
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CO[C@@H]([C@@]1([H])N(CCC1)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(NNC(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)=O)=O)[C@@H](C)C(N[C@H](C(N)=O)CC3=CNC4=CC=CC=C34)=O
Molecular Formula
C55H86N10O11
Molecular Weight
1063.33
References & Citations
[1]Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 May. 16 (5) :893-904.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
